Eleusis

Today we announced that we have acquired @EleusisLtd in an all-equity transaction. Beckley Psytech will gain full rights to the company's assets and Eleusis CEO, Shlomi Raz, will be appointed as our Chief Business Officer. Read more here: beckleypsytech.com/posts/beckley-…

To explore #psychedelics' full potential, Eleusis is developing a psilocin drug candidate, designing cost-effective delivery platforms, and evaluating potential immunomodulation and neuroprotection applications. Important info bit.ly/3gjPHEy $SPKB bit.ly/3rn0B2z

ELE-Psilo is a proprietary psilocin salt formulation being developed for IV infusion with the goal of faster onset and shorter duration than that observed in third party clinical studies of oral psilocybin. Important info: bit.ly/3gjPHEy bit.ly/3qr1zu7

Eleusis CEO Shlomi Raz spoke to @endpts' @Nicole_DeFeudis about ELE-Psilo's potential to provide greater control over treatment intensity and duration, which can potentially help overcome the current logistical burdens of #psychedelic therapy. bit.ly/3Ln6Ri6

Several members of our team sat down with @lucidnewssite @blossomact to discuss our goals to develop psychedelic therapies that are convenient, accessible and affordable, and share how Eleusis’s Phase 1b study with LSD informed our strategy. lucid.news/whats-the-best…

Eleusis plans to develop ELE-Psilo as a rapid-acting treatment for major depressive disorder and anticipates ELE-Psilo will enter clinical trials in the UK in 2022. Learn about our US PTO Notice of Allowance on our ELE-Psilo patent here: bit.ly/3iLCd5M #depression

ELE-Psilo is an investigational #psychedelic drug candidate designed to deliver #psilocybin’s active ingredient – #psilocin – by intravenous infusion.

We are pleased to announce Eleusis has received a Notice of Allowance for our proprietary #psilocin salt form & accompanying formulations, which are being developed as Eleusis' lead drug candidate, ELE-Psilo, from the US Patent and Trademark Office. bit.ly/3iLCd5M

Making a #psilocybin-based investigational drug candidate compatible w/ the current healthcare system requires 2 things: drug development & bespoke care delivery. Learn how Eleusis is working on both. Important info bit.ly/3gjPHEy $SPKB @biospace bit.ly/36cAHqh

Eleusis’ Shlomi Raz & Andala’s Kathy Kaluhiokalani spoke w/@biospace about Eleusis’ efforts to transform potential #psychedelic therapies like psilocin into FDA-approved treatments compatible w/ our healthcare system. Important info bit.ly/3gjPHEy bit.ly/36cAHqh

Research into psilocybin's antidepressant effects has revealed both exciting clinical potential & practical limitations. Eleusis is developing ELE-Psilo, a psilocybin-based investigational drug candidate, as a potential modern depression treatment. bit.ly/3qKVjh3 $SPKB

Eleusis plans to merge with Silver Spike Acquisition Corp II to accelerate our development of ELE-Psilo. Learn about our merger & ongoing work seeking to provide new hope to patients suffering from #depression: bit.ly/3AgudSj $SPKB

Eleusis is focused on developing 2nd gen investigational psychedelics. If successfully developed & approved, we believe they have the potential to revolutionize depression treatment. View our video bit.ly/3AgudSj & website to learn more: bit.ly/3rn0B2z $SPKB

See how Eleusis is working to transform investigational #psychedelics into modern therapies bit.ly/3qKVjh3 $SPKB

ELE-Psilo, is designed to be a 2nd generation class of #psilocybin in development for the treatment of #depression and with the potential to offer a consistent, controlled and convenient experience for patients. bit.ly/34KFJtc $SPKB

An estimated 300M people worldwide are impacted by depression yet current antidepressant options often fall short of patient needs. We believe dev. of 2nd gen. #Psychedelic drug candidates holds the potential to transform treatment of #depression. bit.ly/3AgudSj $SPKB

Eleusis is developing a new therapy designed to deliver #psilocybin’s active ingredient by IV infusion as a safe, consistent & cost-effective alternative to oral psilocybin. Learn how ELE-Psilo has the potential to mainstream #psychedelic treatment: bit.ly/34KFJtc $SPKB

Eleusis is dedicated to developing investigational #psychedelics with the goal of transforming them into modern medicines. Learn how our team is working to design product candidates that, if approved, could be convenient, personalized and affordable. $SPKB bit.ly/3AnDJmp

A week ago, Eleusis began the exciting next chapter in our work to unlock #psilocybin's breakthrough potential for treating #depression when we announced our merger with Silver Spike Acquisition Corp. II. bit.ly/33sItLP $SPKB

Our CEO, Shlomi Raz, underscores Eleusis' dedication to providing next-generation #psychedelic therapies that have the potential to transform the treatment of #depression and address a wide range of unmet needs. bit.ly/3qKVjh3 $SPKB